Breast cancer treatment-induced cardiotoxicity

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer J Int Cancer. 2015;136:E359–386.
   PubMed Web of Science ®Google Scholar
• Cancer of the Breast (Female) - SEER Stat Fact Sheets [Internet]. [cited 2015 Nov 25]. Available from: http://seer.cancer.gov/statfacts/html/breast.html
   Google Scholar
• Sledge GW, Mamounas EP, Hortobagyi GN, et al. Past, present, and future challenges in breast cancer treatment. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:1979–1986.
   PubMed Web of Science ®Google Scholar
• Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;2016(37):2768–2801.
   Web of Science ®Google Scholar
• Ewer MS, Ewer SM. Cardiotoxicity of anticancer treatments. Nat Rev Cardiol. 2015;12:547–558.
   PubMed Web of Science ®Google Scholar
• Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869–2879.
   PubMed Web of Science ®Google Scholar
• Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer [Internet]. 2010;10. [cited 2017 Feb 27]. Available from: http://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-10-337
   Web of Science ®Google Scholar
• Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–983.
   PubMed Web of Science ®Google Scholar
• Sawyer DB. Anthracyclines and heart failure. N Engl J Med. 2013;368:1154–1156.
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 2012;18:1639–1642.
   PubMed Web of Science ®Google Scholar
• Steinberg JS, Cohen AJ, Wasserman AG, et al. Acute arrhythmogenicity of doxorubicin administration. Cancer. 1987;60:1213–1218.
   PubMed Web of Science ®Google Scholar
• Kilickap S, Akgul E, Aksoy S, et al. Doxorubicin-induced second degree and complete atrioventricular block. Europace. 2005;7:227–230.
   PubMed Web of Science ®Google Scholar
• Rudzinski T, Ciesielczyk M, Religa W, et al. Doxorubicin-induced ventricular arrhythmia treated by implantation of an automatic cardioverter-defibrillator. Europace. 2007;9:278–280.
   PubMed Web of Science ®Google Scholar
• Von Hoff DD, Rozencweig M, Layard M, et al. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med. 1977;62:200–208.
   PubMed Web of Science ®Google Scholar
• Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35:893–911.
   PubMed Web of Science ®Google Scholar
• Evandro DA. Evaluation of cardiac toxicities in breast cancer patients treated with adjuvant chemotherapy and/or anti-HER2 targeted agents: late cardiac side-effects. page 18. Université Libre De Bruxelles. 2015.
   Google Scholar
• Saif MW, Shah MM, Shah AR. Fluoropyrimidine-associated cardiotoxicity: revisited. Expert Opin Drug Saf. 2009;8:191–202.
   PubMed Web of Science ®Google Scholar
• Südhoff T, Enderle M-D, Pahlke M, et al. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol Off J Eur Soc Med Oncol. 2004;15:661–664.
   PubMed Web of Science ®Google Scholar
• Polk A, Vaage-Nilsen M, Vistisen K, et al. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: a systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974–984.
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, McGuire WP, Guarnieri T, et al. Cardiac disturbances during the administration of taxol. J Clin Oncol Off J Am Soc Clin Oncol. 1991;9:1704–1712.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. The Lancet. 2012;379:432–444.
   PubMed Web of Science ®Google Scholar
• Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med. 2005;352:2302–2313.
   PubMed Web of Science ®Google Scholar
• Subar M, Muggia FM. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep. 1986;70:690–691.
   PubMedGoogle Scholar
• Zabernigg A, Gattringer C. Myocardial infarction associated with vinorelbine (navelbine). Eur J Cancer Oxf Engl. 1996;32A:1618–1619.
   PubMed Web of Science ®Google Scholar
• Mandel EM, Lewinski U, Djaldetti M. Vincristine-induced myocardial infarction. Cancer. 1975;36:1979–1982.
   PubMed Web of Science ®Google Scholar
• FDA. Highlights of prescribing information: HALAVENTM (eribulin mesylate) [Internet]. [cited 2017 Jul 01]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201532lbl.pdf
   Google Scholar
• Braverman AC, Antin JH, Plappert MT, et al. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens. J Clin Oncol Off J Am Soc Clin Oncol. 1991;9:1215–1223.
   PubMed Web of Science ®Google Scholar
• Yano S, Shimada K. Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer. Jpn Circ J. 1996;60:185–188.
   PubMedGoogle Scholar
• Cardoso F, Costa A, Senkus E, et al. 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2016;mdw544.
   Web of Science ®Google Scholar
• Denduluri N, Somerfield MR, Eisen A, et al. Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2016; 34:2416-2427
   Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182.
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–137.
   PubMed Web of Science ®Google Scholar
• Belmonte F, Das S, Sysa-Shah P, et al. ErbB2 overexpression upregulates antioxidant enzymes, reduces basal levels of reactive oxygen species, and protects against doxorubicin cardiotoxicity. Am J Physiol Heart Circ Physiol. 2015;309:H1271–1280.
   PubMed Web of Science ®Google Scholar
• Kuramochi Y, Guo X, Sawyer DB. Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol. 2006;41:228–235.
   PubMed Web of Science ®Google Scholar
• Liu X, Gu X, Li Z, et al. Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol. 2006;48:1438–1447.
   PubMed Web of Science ®Google Scholar
• Pondé NF, Lambertini M, de Azambuja E. Twenty years of anti-HER2 therapy-associated cardiotoxicity. ESMO Open. 2016;1:e000073.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, du Bois A.Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:1999–2006.
   PubMed Web of Science ®Google Scholar
• Von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer: a German breast group 26/breast international group 03-05 study. Eur J Cancer Oxf Engl. 1990;2011(47):2273–2281.
   Google Scholar
• Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:5529–5537.
   PubMed Web of Science ®Google Scholar
• Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Lond Engl. 2010;375:377–384.
   PubMed Web of Science ®Google Scholar
• Untch M, Rezai M, Loibl S, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:2024–2031.
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Suman VJ, Meric-Bernstam F, et al. Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:1317–1325.
   PubMed Web of Science ®Google Scholar
• Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet Lond Engl. 2017;389:1195–1205.
   PubMed Web of Science ®Google Scholar
• Romond EH, Jeong J-H, Rastogi P, et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012;30:3792–3799.
   PubMed Web of Science ®Google Scholar
• Advani PP, Ballman KV, Dockter TJ, et al. Long-term cardiac safety analysis of NCCTG N9831 (alliance) adjuvant trastuzumab trial. J Clin Oncol Off J Am Soc Clin Oncol. 2015;34:581-587
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011;365:1273–1283.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Eiermann W, Robert NJ, et al. Ten year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel (AC→T) with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2+ early breast cancer. Abstract S5-04; Sabcs. 2015.
   Google Scholar
• Spielmann M, Roche H, Delozier T, et al. Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol. 2009;27:6129–6134.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354:809–820.
   PubMed Web of Science ®Google Scholar
• Pivot X, Suter T, Nabholtz JM, et al. Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III study. Eur J Cancer Oxf Engl. 1990;2015(51):1660–1666.
   Google Scholar
• Piotrowski G, Gawor R, Stasiak A, et al. Cardiac complications associated with trastuzumab in the setting of adjuvant chemotherapy for breast cancer overexpressing human epidermal growth factor receptor type 2 – a prospective study. Arch Med Sci. 2012;2:227–235.
   Web of Science ®Google Scholar
• de Azambuja E, Procter MJ, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:2159–2165.
   PubMed Web of Science ®Google Scholar
• Tan-Chiu E, Yothers G, Romond E, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:7811–7819.
   PubMed Web of Science ®Google Scholar
• Suter TM, Procter M, van Veldhuisen DJ, et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:3859–3865.
   PubMed Web of Science ®Google Scholar
• Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncol. 2012;23:vii155–vii166.
   PubMed Web of Science ®Google Scholar
• Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724–734.
   PubMed Web of Science ®Google Scholar
• Swain SM, Ewer MS, Cortés J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. The Oncologist. 2013;18:257–264.
   PubMed Web of Science ®Google Scholar
• Portera CC, Walshe JM, Rosing DR, et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with [corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:2710–2716.
   PubMed Web of Science ®Google Scholar
• Gianni L, Lladó A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:1131–1137.
   PubMed Web of Science ®Google Scholar
• Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:1138–1144.
   PubMed Web of Science ®Google Scholar
• Cortés J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:1594–1600.
   PubMed Web of Science ®Google Scholar
• Dang C, Iyengar N, Datko F, et al. Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:442–447.
   PubMed Web of Science ®Google Scholar
• Urruticoechea A, Rizwanullah M, Im S-A, et al. PHEREXA: a phase III study of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) for patients (pts) who progressed during/after one line of H-based therapy in the HER2-positive metastatic breast cancer (MBC) setting. J Clin Oncol [Internet]. 2016;34. [cited 2017 Apr 25]. Available from: http://meetinglibrary.asco.org/content/162688-176
   Web of Science ®Google Scholar
• Gianni L, Pienkowski T, Im Y-H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13:25–32.
   PubMed Web of Science ®Google Scholar
• Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol Off J Eur Soc Med Oncol. 2013;24:2278–2284.
   PubMed Web of Science ®Google Scholar
• Rimawi MF, Cecchini RS, Rastogi P, et al. A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) ± estrogen deprivation: NRG Oncology/NSABP B-52. San Antonio Breast Cancer Symposium. 2016; Abstract S3–06.
   Google Scholar
• von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med [Internet]. 2017 [cited 2017 Jun 27]. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1703643
   PubMed Web of Science ®Google Scholar
• Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783–1791.
   PubMed Web of Science ®Google Scholar
• Krop IE, Kim S-B, González-Martín A, et al. Trastuzumab emtansine versus treatment of physician’s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:689–699.
   PubMed Web of Science ®Google Scholar
• Perez EA, Barrios C, Eiermann W, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:141–148.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Gluz O, Christgen M, et al. Final analysis of WSG-ADAPT HER2+/HR+ phase II trial: efficacy, safety, and predictive markers for 12-weeks of neoadjuvant TDM1 with or without endocrine therapy versus trastuzumab+endocrine therapy in HER2-positive hormone-receptor-positive early breast cancer. San Antonio Breast Cancer Symposium. 2015; Abstract: S5-03.
   Google Scholar
• Martin M, Fumoleau P, Dewar JA, et al. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Ann Oncol Off J Eur Soc Med Oncol. 2016;27:1249–1256.
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Martin M, Symmans WF, et al. Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE). J Clin Oncol. 2016;34(suppl):Abstract 500.
   Google Scholar
• Burris HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol Off J Am Soc Clin Oncol. 2011;29:398–405.
   PubMed Web of Science ®Google Scholar
• Krop IE, LoRusso P, Miller KD, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:3234–3241.
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Dirix L, Kocsis J, et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:1157–1163.
   PubMed Web of Science ®Google Scholar
• Gupta M, Wang B, Carrothers TJ, et al. Effects of trastuzumab emtansine (T-DM1) on QT interval and safety of pertuzumab plus T-DM1 in patients with previously treated human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Pharmacol Drug Dev. 2013;2:11–24.
   PubMed Web of Science ®Google Scholar
• Miller KD, Diéras V, Harbeck N, et al. Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:1437–1444.
   PubMed Web of Science ®Google Scholar
• Krop IE, Suter TM, Dang CT, et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Apr 1;33(10):1136–1142.
   PubMed Web of Science ®Google Scholar
• Spector NL, Yarden Y, Smith B, et al. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells. Proc Natl Acad Sci USA. 2007;104:10607–10612.
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733–2743.
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Oliva C, et al. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. The Oncologist. 2010;15:924–934.
   PubMed Web of Science ®Google Scholar
• Johnston S, Pippen J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:5538–5546.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:5544–5552.
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:1124–1130.
   PubMed Web of Science ®Google Scholar
• Guan Z, Xu B, DeSilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31:1947–1953.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Cirrincione CT, Barry WT, et al. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:3959–3966.
   PubMed Web of Science ®Google Scholar
• Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1574–1583.
   PubMed Web of Science ®Google Scholar
• Pivot X, Manikhas A, Żurawski B, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1564–1573.
   PubMed Web of Science ®Google Scholar
• Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol. 2012;13:135–144.
   PubMed Web of Science ®Google Scholar
• Robidoux A, Tang G, Rastogi P, et al. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol. 2013;14:1183–1192.
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15:1137–1146.
   PubMed Web of Science ®Google Scholar
• Goss PE, Smith IE, O’Shaughnessy J, et al. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol. 2013;14:88–96.
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart M, Holmes E, Baselga J, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:1034–1042.
   PubMed Web of Science ®Google Scholar
• Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet Lond Engl. 2012;379:633–640.
   PubMed Web of Science ®Google Scholar
• Zhang X, Munster PN. New protein kinase inhibitors in breast cancer: afatinib and neratinib. Expert Opin Pharmacother. 2014;15:1277–1288.
   PubMed Web of Science ®Google Scholar
• Awada A, Colomer R, Inoue K, et al. Neratinib plus paclitaxel vs trastuzumab plus paclitaxel in previously untreated metastatic erbb2-positive breast cancer: the NEfERT-T randomized clinical trial. JAMA Oncol. 2016;2:1557–1564.
   PubMed Web of Science ®Google Scholar
• Harbeck N, Huang C-S, Hurvitz S, et al. Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial. Lancet Oncol. 2016;17:357–366.
   PubMed Web of Science ®Google Scholar
• Chan A, Delaloge S, Holmes FA, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2016;17:367–377.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Sun Y, Dirix LY, et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:1301–1307.
   PubMed Web of Science ®Google Scholar
• Awada A, Dirix L, Manso Sanchez L, et al. Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:109–116.
   PubMed Web of Science ®Google Scholar
• Chow LW-C, Xu B, Gupta S, et al. Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer. Br J Cancer. 2013;108:1985–1993.
   PubMed Web of Science ®Google Scholar
• Martin M, Bonneterre J, Geyer CE, et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. Eur J Cancer Oxf Engl. 1990;2013(49):3763–3772.
   Google Scholar
• Saura C, Garcia-Saenz JA, Xu B, et al. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:3626–3633.
   PubMed Web of Science ®Google Scholar
• Freedman RA, Gelman RS, Wefel JS, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: a phase II trial of neratinib for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34:945–952.
   PubMed Web of Science ®Google Scholar
• Park JW, Liu MC, Yee D, et al. Adaptive randomization of neratinib in early breast cancer. N Engl J Med. 2016;375:11–22.
   PubMed Web of Science ®Google Scholar
• Jacobs SA, Robidoux A, Garcia JM, et al. NSABP FB-7: a phase II randomized trial evaluating neoadjuvant therapy with weekly paclitaxel (P) plus neratinib (N) or trastuzumab (T) or neratinib and trastuzumab (NþT) followed by doxorubicin and cyclophosphamide (AC) with postoperative T in women with locally advanced HER2-positive breast cancer. San Antonio Breast Cancer Symposium. 2015;Abstract PG5–04.
   Google Scholar
• Lin NU, Winer EP, Wheatley D, et al. A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab. Breast Cancer Res Treat. 2012;133:1057–1065.
   PubMed Web of Science ®Google Scholar
• Schuler M, Awada A, Harter P, et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2012;134:1149–1159.
   PubMed Web of Science ®Google Scholar
• Cortés J, Dieras V, Ro J, et al. Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncol. 2015;16:1700–1710.
   PubMed Web of Science ®Google Scholar
• Gunzer K, Joly F, Ferrero J-M, et al. A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole. SpringerPlus. 2016;5:45.
   PubMed Web of Science ®Google Scholar
• Hanusch C, Schneeweiss A, Loibl S, et al. Dual blockade with afatinib and trastuzumab as neoadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy-DAFNE (GBG-70). Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21:2924–2931.
   PubMed Web of Science ®Google Scholar
• Rimawi MF, Aleixo SB, Rozas AA, et al. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer. Clin Breast Cancer. 2015;15:101–109.
   PubMed Web of Science ®Google Scholar
• Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340:1801–1811.
   PubMed Web of Science ®Google Scholar
• Cole MP, Jones CT, Todd ID. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer. 1971;25:270–275.
   PubMed Web of Science ®Google Scholar
• Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by nolvadex adjuvant trial organisation. Lancet Lond Engl. 1983;1:257–261.
   PubMedGoogle Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet Lond Engl. 2005;365:1687–1717.
   PubMed Web of Science ®Google Scholar
• Ragaz J, Coldman A. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes. J Clin Oncol Off J Am Soc Clin Oncol. 1998;16:2018–2024.
   PubMed Web of Science ®Google Scholar
• Decensi A, Maisonneuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation. 2005;111:650–656.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer–96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272–282.
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388.
   PubMed Web of Science ®Google Scholar
• Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 1991;9:286–294.
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989;320:479–484.
   PubMed Web of Science ®Google Scholar
• Bruning PF, Bonfrer JM, Hart AA, et al. Tamoxifen, serum lipoproteins and cardiovascular risk. Br J Cancer. 1988;58:497–499.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Allen D, Baum M, et al. Long term effects of tamoxifen. Biological effects of tamoxifen working party. Eur J Cancer Oxf Engl. 1992;29A:15–21.
   PubMed Web of Science ®Google Scholar
• Dewar JA, Horobin JM, Preece PE, et al. Long term effects of tamoxifen on blood lipid values in breast cancer. Bmj. 1992;305:225–226.
   PubMed Web of Science ®Google Scholar
• Grainger DJ, Schofield PM. Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence. Circulation. 2005;112:3018–3024.
   PubMed Web of Science ®Google Scholar
• Guetta V, Lush RM, Figg WD, et al. Effects of the antiestrogen tamoxifen on low-density lipoprotein concentrations and oxidation in postmenopausal women. Am J Cardiol. 1995;76:1072–1073.
   PubMed Web of Science ®Google Scholar
• Love RR, Wiebe DA, Feyzi JM, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment. J Natl Cancer Inst. 1994;86:1534–1539.
   PubMed Web of Science ®Google Scholar
• Ades F, Zardavas D, Pinto AC, et al. Cardiotoxicity of systemic agents used in breast cancer. Breast Edinb Scotl. 2014;23:317–328.
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Temin S, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update. J Clin Oncol. 2014;32:2255–2269.
   PubMed Web of Science ®Google Scholar
• Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol Off J Eur Soc Med Oncol. 2017;28:487–496.
   PubMed Web of Science ®Google Scholar
• Khosrow-Khavar F, Filion KB, Al-Qurashi S, et al. Cardiotoxicity of aromatase inhibitors and tamoxifen in post-menopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials. Ann Oncol Off J Eur Soc Med Oncol. 2016.
   Google Scholar
• Blondeaux E, Musio D, Bruzzi P, et al. Treatment with aromatase inhibitors and markers of cardiovascular disease. Breast Cancer Res Treat. 2016;160:261–267.
   PubMed Web of Science ®Google Scholar
• Blok EJ, van de Velde CJH, Meershoek-Klein Kranenbarg EM, et al. Optimal duration of extended letrozole treatment after 5 years of adjuvant endocrine therapy; results of the randomized phase III IDEAL trial (BOOG 2006-05). San Antonio Breast Cancer Symposium. 2016; Abstract S1–04.
   Google Scholar
• Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med. 2016;375:209–219.
   PubMed Web of Science ®Google Scholar
• Tjan-Heijnen VC, Van Hellemond IE, Peer PG, et al. First results from the multicenter phase III DATA study comparing 3 versus 6 years of anastrozole after 2-3 years of tamoxifen in postmenopausal women with hormone receptor-positive early breast cancer. San Antonio Breast Cancer Symposium. 2016; Abstract S1–03.
   Google Scholar
• Mamounas EP, Bandos H, Lembersky BC, et al. A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): results from NRG Oncology/NSABP B-42. San Antonio Breast Cancer Symposium. 2016; Abstract S1–05.
   Google Scholar
• Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:4594–4600.
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson JFR, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22:1605–1613.
   PubMed Web of Science ®Google Scholar
• Howell A, Pippen J, Elledge RM, et al. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. Cancer. 2005;104:236–239.
   PubMed Web of Science ®Google Scholar
• Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor–positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664–1670.
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366:520–529.
   PubMed Web of Science ®Google Scholar
• Rugo HS, Pritchard KI, Gnant M, et al. Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Ann Oncol Off J Eur Soc Med Oncol. 2014;25:808–815.
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016.
   PubMed Web of Science ®Google Scholar
• Finn RS, Martin M, Rugo HS, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–1936.
   PubMed Web of Science ®Google Scholar
• Turner NC, Ro J, André F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219.
   PubMed Web of Science ®Google Scholar
• Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35.
   PubMed Web of Science ®Google Scholar
• Aseyev O, Johnson C, Turek M, et al. Abstract P2-07-06: obesity, dyslipidemia, and diabetes as risk factors for trastuzumab-related cardiotoxicity in breast cancer patients. Cancer Res. 2017;77:P2-07-06-P2-07–06.
   Web of Science ®Google Scholar
• Ezaz G, Long JB, Gross CP, et al. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014;3:e000472–e000472.
   PubMed Web of Science ®Google Scholar
• Senkus E, Kyriakides S, Ohno S, et al. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v8–v30.
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Grant AD, Negishi T, et al. Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes. J Am Coll Cardiol. 2013;61:77–84.
   PubMed Web of Science ®Google Scholar
• van Royen N, Jaffe CC, Krumholz HM, et al. Comparison and reproducibility of visual echocardiographic and quantitative radionuclide left ventricular ejection fractions. Am J Cardiol. 1996;77:843–850.
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Wintersperger BJ, Flamm SD, et al. Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review. Circ Cardiovasc Imaging. 2013;6:1080–1091.
   PubMed Web of Science ®Google Scholar
• Zardavas D, Suter TM, Van Veldhuisen DJ, et al. Role of troponins I and T and N -terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2–positive breast cancer receiving trastuzumab: a herceptin adjuvant study cardiac marker substudy. J Clin Oncol. 2017;35:878–884.
   PubMed Web of Science ®Google Scholar
• de Azambuja E, Bradbury I, Ewer M, et al. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06). San Antonio Breast Cancer Symposium. 2016; Abstract P4-21-09.
   Google Scholar
• Schneider BP, Shen F, Gardner L, et al. Genome-wide association study for anthracycline-induced congestive heart failure. Clin Cancer Res Off J Am Assoc Cancer Res. 2017;23:43–51.
   PubMed Web of Science ®Google Scholar
• Stanton SE, Ward MM, Christos P, et al. Pro1170 Ala polymorphism in HER2-neu is associated with risk of trastuzumab cardiotoxicity. BMC Cancer. 2015;15:267.
   PubMed Web of Science ®Google Scholar
• Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101–Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017;35:870–877.
   PubMed Web of Science ®Google Scholar
• Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37:1671–1680.
   PubMed Web of Science ®Google Scholar
• Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol Off J Am Soc Clin Oncol. 2009;27:1177–1183.
   PubMed Web of Science ®Google Scholar
• Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in Early Breast Cancer: the ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol Off J Am Soc Clin Oncol. 2017;JCO2016714147.
   Google Scholar